A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Clinical trial NCT07082192 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07082192
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-29
- Primary completion
- 2027-09-30
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.